Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26‐week, open‐label, multicentre study: The LixiLan JP‐O2 randomized clinical trial
Open Access
- 14 April 2020
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (S4) , 14-23
Abstract
Aims: To assess efficacy and safety of 26‐week treatment with insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) compared with insulin glargine U100 (iGlar) in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs). Materials and Methods: This phase 3, multicentre, open‐label, 1:1 randomized, parallel‐group study compared efficacy of iGlarLixi and iGlar in patients with T2DM, HbA1c of ≥7.5% to ≤9.5% and fasting plasma glucose ≤10.0 mmol/L (180 mg/dL). The primary endpoint was change in HbA1c from baseline to week 26. Results: Patients were randomized to iGlarLixi (n = 260) or iGlar (n = 261) (mean age 59.7 years, baseline BMI 26.04 kg/m 2 , and HbA1c 8.04% [64.4 mmol/mol]). HbA1c reduction was significantly greater with iGlarLixi (−1.40% [−15.3 mmol/mol]) than with iGlar (−0.76% [−8.3 mmol/mol]). Significantly more iGlarLixi patients reached HbA1c P < .0001), with significantly lower weight gain (LS mean difference −1.06 kg, P < .0001). Documented symptomatic hypoglycemia (plasma glucose ≤3.9 mmol/L [70 mg/dL]) was recorded in 14.2% of patients with iGlarLixi and 12.3% with iGlar. No severe hypoglycemia was reported in either group. Other than the expected gastrointestinal issues associated with glucagon‐like peptide 1 receptor agonists, we found no major difference in the incidence of TEAEs. Conclusions: HbA1c reduction was significantly greater with iGlarLixi than with iGlar; significantly more patients achieved HbA1c <7%, with no additional risk of hypoglycemia and without weight gain. iGlarLixi (1:1) provided an effective treatment option for Japanese patients with T2DM inadequately controlled on OADs. Clinical Trial Number: NCT02752828Keywords
Funding Information
- Sanofi
This publication has 19 references indexed in Scilit:
- Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectivesJournal of Diabetes Investigation, 2016
- Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effectsDiabetes/Metabolism Research and Reviews, 2015
- Ethnic Differences in Insulin Sensitivity, β-Cell Function, and Hepatic Extraction Between Japanese and Caucasians: A Minimal Model AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2014
- Differences in the HbA1c ‐lowering efficacy of glucagon‐like peptide‐1 analogues between Asians and non‐Asians: a systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2014
- Clinical Inertia in People With Type 2 DiabetesDiabetes Care, 2013
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysisDiabetologia, 2013
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNature Reviews Endocrinology, 2012
- Dosing of Insulin Glargine to Achieve the Treatment Target in Japanese Type 2 Diabetes on a Basal Supported Oral Therapy Regimen in Real Life: ALOHA Study SubanalysisDiabetes Technology & Therapeutics, 2012
- Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)Diabetes, Obesity and Metabolism, 2012
- Barriers towards insulin therapy in type 2 diabetic patients: results of an observational longitudinal studyHealth and Quality of Life Outcomes, 2010